Effects of Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 in Radiation-Induced Intestinal Injury

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 3, 2009, Pages 942-948

  Abderrahmani, Rym ^a   François, Agnès ^a   Buard, Valérie ^a   Benderitter, Marc ^a   Sabourin, Jean Christophe ^b   Crandall, David L ^c   Milliat, Fabien ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c PFIZER INC   (United States)

Author keywords

Intestinal injury; Ionizing radiation; PAI 1; Pharmacological inhibition

Indexed keywords

BENEFICIAL EFFECTS; GENETIC DEFICIENCIES; INTESTINAL INJURY; INVESTIGATE EFFECTS; KNOCKOUT MICE; MATRIX PROTEINS; MOUSE MODELS; PAI-1; PHARMACOLOGICAL INHIBITION; PLASMINOGEN ACTIVATOR INHIBITOR-1; RADIATION INJURY; RADIATION-INDUCED; REAL-TIME PCR; SINGLE-DOSE; TISSUE INJURY; TRANSFORMING GROWTH FACTORS; WILD TYPES;

ANIMALS; BIOACTIVITY; CHEMICAL MODIFICATION; ENZYME INHIBITION; GENE EXPRESSION; IONIZING RADIATION; IRRADIATION; PLASMAS; RADIATION EFFECTS; RADIATION SHIELDING; RADIOACTIVITY;

MOS CAPACITORS;

COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 2; CONNECTIVE TISSUE GROWTH FACTOR; PAI 039; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GENE EXPRESSION; GENETIC DISORDER; HISTOPATHOLOGY; INJURY SEVERITY; INTESTINE INJURY; IRRADIATION; KNOCKOUT MOUSE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION INJURY; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, DIFFERENTIATION; COLLAGEN; COLLAGEN TYPE III; CONNECTIVE TISSUE GROWTH FACTOR; GENE EXPRESSION; INDOLEACETIC ACIDS; INTESTINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; RADIATION INJURIES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67049134559     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.01.077     Document Type: Article

References (35)

1. Denham J.W., and Hauer-Jensen M. The radiotherapeutic injury: A complex "wound.". Radiother Oncol 63 (2002) 129-145
2. Stone H.B., Coleman C.N., Anscher M.S., et al. Effects of radiation on normal tissue: Consequences and mechanisms. Lancet Oncol 4 (2003) 529-536
3. Bentzen S.M. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 6 (2006) 702-713
4. Martin M., Lefaix J., and Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?. Int J Radiat Oncol Biol Phys 47 (2000) 277-290
5. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342 (2000) 1792-1801
6. Brown N.J., Nakamura S., Ma L., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58 (2000) 1219-1227
7. Oikawa T., Freeman M., Lo W., et al. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51 (1997) 164-172
8. Vozenin-Brotons M.C., Milliat F., Linard C., et al. Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization. Radiat Res 161 (2004) 299-311
9. Milliat F., Sabourin J.C., Tarlet G., et al. Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy. Am J Pathol 172 (2008) 691-701
10. Baxi S., Crandall D.L., Meier T.R., et al. Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis. Thromb Haemost 99 (2008) 749-758
11. Crandall D.L., Quinet E.M., El Ayachi S., et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 26 (2006) 2209-2215
12. Hennan J.K., Elokdah H., Leal M., et al. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 314 (2005) 710-716
13. Hennan J.K., Morgan G.A., Swillo R.E., et al. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist in a rat model of thrombosis. J Thromb Haemost (2008)
14. Smith L.H., Dixon J.D., Stringham J.R., et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 107 (2006) 132-134
15. Weisberg A.D., Albornoz F., Griffin J.P., et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 25 (2005) 365-371
16. Wang J., Zheng H., Sung C.C., et al. Cellular sources of transforming growth factor-beta isoforms in early and chronic radiation enteropathy. Am J Pathol 153 (1998) 1531-1540
17. Zheng H., Wang J., Koteliansky V.E., et al. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Gastroenterology 119 (2000) 1286-1296
18. Ma L.J., Mao S.L., Taylor K.L., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
19. Milliat F., Francois A., Isoir M., et al. Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages. Am J Pathol 169 (2006) 1484-1495
20. Hauer-Jensen M., Fink L.M., and Wang J. Radiation injury and the protein C pathway. Crit Care Med 32 (2004) S325-S330
21. Potten C.S., Owen G., and Roberts S.A. The temporal and spatial changes in cell proliferation within the irradiated crypts of the murine small intestine. Int J Radiat Biol 57 (1990) 185-199
22. Qiu W., Carson-Walter E.B., Liu H., et al. PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2 (2008) 576-583
23. Burdelya L.G., Krivokrysenko V.I., Tallant T.C., et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320 (2008) 226-230
24. Paris F., Fuks Z., Kang A., et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293 (2001) 293-297
25. Balsara R.D., Castellino F.J., and Ploplis V.A. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 281 (2006) 22527-22536
26. Gorlatova N.V., Cale J.M., Elokdah H., et al. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 282 (2007) 9288-9296
27. Huang Y., Haraguchi M., Lawrence D.A., et al. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112 (2003) 379-388
28. Eitzman D.T., McCoy R.D., Zheng X., et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97 (1996) 232-237
29. Eitzman D.T., Westrick R.J., Xu Z., et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96 (2000) 4212-4215
30. Hattori N., Degen J.L., Sisson T.H., et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 106 (2000) 1341-1350
31. Takeshita K., Hayashi M., Iino S., et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 164 (2004) 449-456
32. Chan J.C., Duszczyszyn D.A., Castellino F.J., et al. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159 (2001) 1681-1688
33. Gardell S.J., Krueger J.A., Antrilli T.A., et al. Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action. Mol Pharmacol 72 (2007) 897-906
34. Rupin A., Gaertner R., Mennecier P., et al. S35225 is a direct inhibitor of plasminogen activator inhibitor type-1 activity in the blood. Thromb Res 122 (2008) 265-270
35. Verbeke K., Gils A., and Declerck P.J. Inhibition of plasminogen activator inhibitor-1: Antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs. J Thromb Haemost 2 (2004) 298-305